GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jianmin Pharmaceutical Group Co Ltd (SHSE:600976) » Definitions » Total Assets

Jianmin Pharmaceutical Group Co (SHSE:600976) Total Assets : ¥4,205 Mil (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Jianmin Pharmaceutical Group Co Total Assets?

Jianmin Pharmaceutical Group Co's Total Assets for the quarter that ended in Sep. 2024 was ¥4,205 Mil.

Warning Sign:

If a company builds assets at 20.1% a year, faster than its revenue growth rate of 15.8% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Jianmin Pharmaceutical Group Co's average Total Assets Growth Rate was 5.00% per year. During the past 3 years, the average Total Assets Growth Rate was 19.90% per year. During the past 5 years, the average Total Assets Growth Rate was 20.10% per year. During the past 10 years, the average Total Assets Growth Rate was 7.40% per year.

During the past 13 years, Jianmin Pharmaceutical Group Co's highest 3-Year average Total Assets Growth Rate was 34.80%. The lowest was -5.60%. And the median was 7.60%.

Total Assets is connected with ROA %. Jianmin Pharmaceutical Group Co's annualized ROA % for the quarter that ended in Sep. 2024 was 7.95%. Total Assets is also linked to Revenue through Asset Turnover. Jianmin Pharmaceutical Group Co's Asset Turnover for the quarter that ended in Sep. 2024 was 0.21.


Jianmin Pharmaceutical Group Co Total Assets Historical Data

The historical data trend for Jianmin Pharmaceutical Group Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jianmin Pharmaceutical Group Co Total Assets Chart

Jianmin Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,928.54 2,417.34 2,856.08 3,440.21 4,167.95

Jianmin Pharmaceutical Group Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,916.17 4,167.95 4,333.57 4,073.09 4,205.32

Jianmin Pharmaceutical Group Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Jianmin Pharmaceutical Group Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=2256.485+1911.467
=4,168

Jianmin Pharmaceutical Group Co's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=2406.276+1799.049
=4,205

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jianmin Pharmaceutical Group Co  (SHSE:600976) Total Assets Explanation

Total Assets is connected with ROA %.

Jianmin Pharmaceutical Group Co's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=329.032/( (4073.094+4205.324)/ 2 )
=329.032/4139.209
=7.95 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Jianmin Pharmaceutical Group Co's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=871.721/( (4073.094+4205.324)/ 2 )
=871.721/4139.209
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Jianmin Pharmaceutical Group Co Total Assets Related Terms

Thank you for viewing the detailed overview of Jianmin Pharmaceutical Group Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Jianmin Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 484 Parrot Avenue, Hanyang District, Wuhan, CHN, 430052
Jianmin Pharmaceutical Group Co Ltd is engaged in the manufacture and distribution of pharmaceutical products. It adheres to the core position of pediatric medicine, gynecological medicine, and special Chinese medicine, it offers products under Jianmin and Longmu brands.
Executives
Du Ming De Director
He Qin Director
Gao Kai senior management
Wang Jun senior management
Huang Zhi Jun senior management
Pei Xue Jun senior management
Bu Zhong Jiang Director
Cheng Chao Yang senior management
Xu Sheng senior management
Hu Zhen Bo senior management
Liu Qin Qiang Director
Xiong Fu Liang senior management
Liu Peng senior management

Jianmin Pharmaceutical Group Co Headlines

No Headlines